CFO4Life Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $440K | Sell |
3,154
-587
| -16% | -$82.2K | 0.07% | 134 |
|
|
2025
Q4 | $459K | Sell |
3,741
-39
| -1% | -$4.74K | 0.07% | 135 |
|
|
2025
Q3 | $420K | Buy |
3,780
+34
| +0.9% | +$3.87K | 0.06% | 141 |
|
|
2025
Q2 | $415K | Buy |
3,746
+30
| +0.8% | +$3.19K | 0.06% | 136 |
|
|
2025
Q1 | $416K | Sell |
3,716
-549
| -13% | -$56.6K | 0.07% | 130 |
|
|
2024
Q4 | $394K | Buy |
4,265
+112
| +3% | +$10.1K | 0.07% | 133 |
|
|
2024
Q3 | $348K | Sell |
4,153
-1,749
| -30% | -$133K | 0.06% | 141 |
|
|
2024
Q2 | $405K | Buy |
5,902
+83
| +1% | +$5.54K | 0.08% | 127 |
|
|
2024
Q1 | $426K | Sell |
5,819
-3,502
| -38% | -$269K | 0.08% | 123 |
|
|
2023
Q4 | $755K | Sell |
9,321
-3,925
| -30% | -$305K | 0.14% | 83 |
|
|
2023
Q3 | $993K | Sell |
13,246
-1,434
| -10% | -$110K | 0.23% | 55 |
|
|
2023
Q2 | $1.13M | Buy |
14,680
+3,489
| +31% | +$278K | 0.24% | 51 |
|
|
2023
Q1 | $929K | Sell |
11,191
-79
| -0.7% | -$6.54K | 0.21% | 53 |
|
|
2022
Q4 | $968K | Sell |
11,270
-3,229
| -22% | -$256K | 0.21% | 64 |
|
|
2022
Q3 | $894K | Sell |
14,499
-288
| -2% | -$18.2K | 0.24% | 49 |
|
|
2022
Q2 | $901K | Buy |
14,787
+302
| +2% | +$18.7K | 0.22% | 51 |
|
|
2022
Q1 | $861K | Sell |
14,485
-269
| -2% | -$17.2K | 0.18% | 57 |
|
|
2021
Q4 | $1.07M | Buy |
+14,754
| New | +$1.02M | 0.22% | 51 |
|
|
2020
Q3 | – | Sell |
-3,531
| Closed | -$272K | – | 131 |
|
|
2020
Q2 | $272K | Sell |
3,531
-1,153
| -25% | -$88.4K | 0.1% | 97 |
|
|
2020
Q1 | $350K | Sell |
4,684
-1,528
| -25% | -$106K | 0.19% | 74 |
|
|
2019
Q4 | $404K | Buy |
6,212
+138
| +2% | +$8.99K | 0.17% | 80 |
|
|
2019
Q3 | $385K | Buy |
6,074
+38
| +0.6% | +$2.48K | 0.17% | 80 |
|
|
2019
Q2 | $408K | Buy |
6,036
+952
| +19% | +$62.6K | 0.19% | 78 |
|
|
2019
Q1 | $331K | Sell |
5,084
-858
| -14% | -$57K | 0.16% | 86 |
|
|
2018
Q4 | $372K | Buy |
5,942
+29
| +0.5% | +$2.03K | 0.16% | 81 |
|
|
2018
Q3 | $457K | Sell |
5,913
-70
| -1% | -$5.29K | 0.2% | 80 |
|
|
2018
Q2 | $424K | Sell |
5,983
-1,600
| -21% | -$113K | 0.18% | 84 |
|
|
2018
Q1 | $572K | Buy |
7,583
+26
| +0.3% | +$2.07K | 0.48% | 33 |
|
|
2017
Q4 | $541K | Sell |
7,557
-2,538
| -25% | -$193K | 0.43% | 40 |
|
|
2017
Q3 | $818K | Sell |
10,095
-334
| -3% | -$25.5K | 0.66% | 21 |
|
|
2017
Q2 | $738K | Buy |
10,429
+317
| +3% | +$21.1K | 0.68% | 16 |
|
|
2017
Q1 | $687K | Buy |
+10,112
| New | +$711K | 0.62% | 24 |
|
Other funds holding GILD
VCM
VPM
CFO4Life Group's GILD Position: Q1 2026 in Review
CFO4Life Group reduced its Gilead Sciences (GILD) stake by 16% in Q1 2026, selling an estimated $82.2K and leaving 3,154 shares worth $440K. The position accounts for 0.07% of the portfolio, ranked #134.
CFO4Life Group first reported a position in GILD in Q1 2017 and has held it in 32 quarters since. The position peaked at $1.13M in Q2 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- CFO4Life Group held 3,154 shares of Gilead Sciences worth $440K as of Q1 2026.
- CFO4Life Group sold 587 Gilead Sciences shares in Q1 2026, an estimated $82.2K.
- Gilead Sciences made up 0.07% of CFO4Life Group's portfolio in Q1 2026, its #134 holding.
- CFO4Life Group first reported a position in Gilead Sciences in Q1 2017 and has held it in 32 quarters since.
- CFO4Life Group's Gilead Sciences position peaked at $1.13M in Q2 2023.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on CFO4Life Group's 13F filing for Q1 2026, filed 11 May 2026.